Positive Safety Data from First Cohort of Phase I
Clinical Trial Evaluating Healthy Subjects
Intravenously Dosed with RECCE®327
Highlights:
•9 subjects in cohort one intravenously dosed with RECCE®327 at 50mg meet sall
end-points, indicating to be safe and well tolerated
•Independent Safety Committee clears second study cohort to be dosed at 150mg
-a three fold increase in dose per approved protocol
•Second cohort recruited; healthy subjects to be dosed 7January 2022
Positive Safety Data from First Cohort of Phase IClinical Trial...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
44.5¢ |
Change
0.080(21.9%) |
Mkt cap ! $128.6M | |||
| Open | High | Low | Value | Volume |
| 37.5¢ | 44.5¢ | 37.5¢ | $191.2K | 477.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 12222 | 44.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 45.0¢ | 10976 | 2 |
View Market Depth
| Last trade - 16.10pm 25/07/2025 (20 minute delay) ? |
| RCE (ASX) Chart |